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Abstract 18 
During food digestion, proteins are hydrolysed into a large variety of peptides. Some of 19 
these peptides are structurally similar to sequences acting in the organism as endogenous 20 
signals, or hormones. Therefore, homologous food peptides can interact with the same 21 
receptors or enzymes in the organism, and in this form, exert an agonistic or antagonistic 22 
activity. Although this subject has been extensively studied during the last decades, the 23 
evidence of the potential of these dietary peptides to modulate numerous physiological 24 
conditions has been mainly achieved by using in vitro assays. However, it is accepted that 25 
health evidence has to be based on in vivo trials (animals or humans) since the activity of 26 
these molecules depends on the ability of these peptides to reach the target tissue in an active 27 
form, which in turn depends on their structure. This article reviews the literature on the 28 
physiological effects of milk-derived bioactive peptides with special emphasis in the evidence 29 
achieved in animal and human trials.  30 
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1. Introduction 31 
It is recognized that diet is one of the environmental factors that influences our health 32 
and the development of certain diseases. Among the different food components, food proteins 33 
constitute a major nutrient with daily ingests between 95 and 120 g of protein, which is 34 
hydrolysed into a large variety of peptides during gastrointestinal digestion. Some of these 35 
peptides share structural characteristics with endogenous peptides that act in the organism as 36 
hormones, neurotransmitters, or regulatory peptides. These exogenous food-derived peptides 37 
can interact with the same receptors in the organism and exert an agonistic or antagonistic 38 
activity. There are many examples of food-derived peptides structurally similar to endogenous 39 
peptides; one of the most representative examples are opioid peptides, which have been 40 
demonstrated to behave as opioid receptors ligands (Teschemacher, 2003). This group of 41 
food-derived bioactive peptides was the first described in 1979 (Henschen, Lottspeich, Brantl, 42 
& Teschemacher, 1979) and since then, and especially during the last two decades, much 43 
effort has been dedicated to the identification of peptides with different physiological effects. 44 
However, the level of evidence built for these food peptides is diverse. For instance, for 45 
antihypertensive peptides, activity has been demonstrated in animal models and clinical trials, 46 
but for other peptides, bioactivity has been just proven in cell cultures or in vitro assays. In 47 
addition, there are many examples of lack of correlation between in vitro and in vivo results, 48 
mainly due to further degradation of peptides during gastrointestinal digestion, or the 49 
impossibility to reach the target organ in a sufficient amount to exert the physiological effect.  50 
On the other hand, absorption of food-derived peptides is not a requirement to exert a 51 
biological function in the organism. The gut is considered the largest endocrine organ in the 52 
body with a large range of endogenous peptides secreted and receptors expressed. The 53 
gastrointestinal tract is in contact with food digests and therefore, with an important quantity 54 
(and variety) of food-derived peptides. For this reason, the effects of peptides on different 55 
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intestinal functions and health are attracting an increasing interest (Moughan, Fuller, Han, 56 
Kies, Miner-Williams, 2007; Shimizu & Hachimura, 2011). It cannot be disregarded that 57 
given the low bioavailability described for some bioactive peptides, certain observed 58 
physiological effects might be mediated through interaction with receptors located at the gut. 59 
The aim of this paper is to review the literature on the physiological effects of milk-60 
derived bioactive peptides with special emphasis in the evidence achieved in animal and 61 
human trials. A short section deals with the advances on hydrolysis technologies. Finally, a 62 
section with future trends, and challenges on dairy peptides research is included. 63 
 64 
2. Technology: dairy protein hydrolysates 65 
During the last two decades, there has been a growing interest in the use of dairy 66 
hydrolysates containing bioactive peptides as agents for maintaining general health and 67 
preventing chronic human diseases. As a result, several technologies, mainly based on the 68 
enzymatic hydrolysis, have been developed for the production of these bioactive hydrolysates 69 
(Hernández-Ledesma, Recio, Ramos, & Amigo, 2002; Korhonen & Pihlanto, 2006; 70 
McDonagh & Fitzgerald, 1998; Phelan, Aherne, Fitzgerald, & O’Brien, 2009). This strategy 71 
is the main choice, but some disadvantages in the method have been reported, such as the 72 
need for using chemical or thermal processes, to stop the proteolysis reaction that could affect 73 
the final attributes of the hydrolysed proteins (Kosseva, Panesar, Kaur, & Kennedy, 2009). 74 
Immobilization of enzyme molecules over different supports could overcome this problem, 75 
allowing the separation of the enzyme from the protein mixture reaction and, furthermore 76 
making possible its reuse (Madadlou, Sheehan, Emam-Djomeh, & Mousavi, 2011; Marqués 77 
et al., 2011; Rocha, Gonçalves, & Texeira, 2011). In the food industry, the use of enzymatic 78 
membrane reactors represents an interesting technology which allows the protein hydrolysis 79 
and the subsequent separation of peptides generated by microfiltration or chromatography 80 
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techniques, such as size exclusion or ion-exchange chromatography (Welderufael, Gibson, & 81 
Jauregui, 2012). Some studies have applied these methodologies for the recovery of 82 
caseinophosphopeptides (CPPs), antimicrobial, and angiotensin-converting enzyme (ACE)-83 
inhibitory peptides from bovine casein (CN) hydrolysates (Recio & Visser, 1999a; Wu et al., 84 
2013; Zhao, Xu, Yang, & Katiyo, 2013).  85 
Moreover, alternative to traditional methods, subcritical water hydrolysis strategies 86 
have been proposed for dairy hydrolysates production without the need for acids, bases or 87 
enzymes. The study of Espinoza, Morawicki, & Hager (2012) demonstrated successfully 88 
subcritical water hydrolysis of a whey protein isolate (WPI) and evaluated how treatment 89 
conditions (temperature and reaction time) affected the degree of hydrolysis, and the 90 
production, composition and concentration of peptides and free amino acids released. In 91 
addition, high hydrostatic pressure causes substantial modifications to milk proteins, and 92 
ultimately influences their functional properties. The potential utilities of high pressure 93 
treatments in dairy technologies have been reviewed (Chawla, Patil, & Singh, 2011; Da Cruz 94 
et al., 2010; López-Fandiño, 2006). As an example, some studies employing high pressure 95 
conditions have yielded protein hydrolysates with enhanced antioxidant and anti-96 
inflammatory effects in intestinal epithelial cells exposed to hydrogen peroxide (Piccolomini, 97 
Iskandar, Lands, & Kubow, 2012).  98 
 99 
3. Health benefits 100 
3.1. Effects on the cardiovascular system 101 
 Cardiovascular diseases have become a worldwide health problem that goes beyond 102 
socio-economic barriers and equally affects men and women. Diet plays a key role in the 103 
development of the most significant risk factors of these diseases, such as hypertension, 104 
obesity, diabetes, low-grade systemic inflammation, and atherosclerosis. In recent years, 105 
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bioactive milk peptides have gained interest because of their notable antihypertensive, 106 
antioxidant, anti-inflammatory and hypocholesterolemic effects. In this section, the most 107 
current scientific information from cell culture, animal experiments and clinical studies on the 108 
role of milk proteins-derived peptides on cardiovascular diseases is summarised and 109 
discussed. 110 
  111 
3.1.1. Antihypertensive peptides 112 
Elevated blood pressure is one of the major independent risk factors for cardiovascular 113 
disease (Erdmann, Cheung, & Schröder, 2008). ACE (EC 3.4.15.1) is one of the main 114 
regulators of blood pressure; thus, inhibition of this enzyme is considered as one of the 115 
strategies for the treatment of hypertension. In recent years, antihypertensive effects of some 116 
peptides derived from milk proteins have been evaluated by in vitro and in vivo studies, 117 
becoming the best known class of bioactive peptides. One of the greatest challenges in 118 
developing milk peptides as antihypertensive food ingredients has been proving their in vivo 119 
efficacy. It mainly depends on the capacity of peptides, after being orally ingested, to reach 120 
the target organs in an intact and active form. In the last years, studies demonstrating the 121 
bioavailability of potential antihypertensive peptides have been carried out. Most of these 122 
studies aimed to evaluating the resistance of bioactive sequences to gastrointestinal digestion, 123 
and their capacity to be absorbed using cell line models (Quirós, Dávalos, Lasunción, Ramos, 124 
& Recio, 2008; Contreras, Sancho, Recio, & Mills, 2012; Picariello et al., 2013).  125 
The dairy peptides have been evaluated using spontaneously hypertensive rats (SHR), 126 
and the peptide sequences, doses and maximum decrease of systolic blood pressure (SBP) 127 
have been summarised in some reviews (Fitzgerald, Murray, & Walsh, 2004; Hernández-128 
Ledesma, Contreras, & Recio, 2011; Martínez-Maqueda, Miralles, Recio, & Hernández-129 
Ledesma, 2012).  130 
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As shown in Table 1, two strategies have been used to release antihypertensive milk 131 
peptides: milk protein hydrolysis and fermentation. Hydrolysates of whole milk protein, 132 
caseinates and whey proteins using gastric and pancreatic enzymes, alone or in combination, 133 
have shown antihypertensive activity in SHR. As an example, the tryptic CN hydrolysate 134 
containing the peptide corresponding to αs1-CN f(23-34) has been patented and 135 
commercialised as antihypertensive agent under the name of peptide C12®. More recently, in 136 
a pepsin casein hydrolysate, two peptides derived from αs1-CN, with sequences RYLGY and 137 
AYFYPEL, have demonstrated potent SBP reducing effects in SHR (Contreras, Carrón, 138 
Montero, Ramos, & Recio, 2009). The action of pepsin is also required to release the 139 
antihypertensive fragments RRWQWR and WQ from peptide lactoferricin (LFcin) (Ruiz-140 
Giménez et al., 2010). Combination of gastric and pancreatic enzymes has been reported to be 141 
a successful strategy to produce potent antihypertensive peptides from milk proteins (Gómez-142 
Ruiz, Ramos, & Recio, 2007; Nurminen et al., 2000). Similarly, the use of food-grade 143 
enzymes derived from microorganisms have become usual for the release of peptides with 144 
demonstrated SBP reducing effects in SHR (Abubakar, Saito, Kitazawa, Kawai, & Itoh, 1998; 145 
Chen, Tsai, & Pan, 2007; Hernández-Ledesma, Miguel, Amigo, Aleixandre, & Recio, 2007; 146 
Jiang, Tian, Brodkorb, & Huo, 2010; Maeno, Yamamoto, & Takano, 1996; Tsai, Chen, Pan, 147 
Gong, & Chung, 2008) (Table 1). 148 
Another strategy to produce antihypertensive peptides is the use of the proteolytic 149 
system of lactic acid bacteria proteins during the elaboration of fermented milks and cheeses. 150 
The most representative example is the production of the β-CN-derived peptides, IPP and 151 
VPP, in sour milk fermented by Lactobacillus helveticus and Saccharomyces cerevisiae 152 
(Calpis®) with potent decreasing effects on the SBP of SHR (Nakamura, Yamamoto, Sakai, & 153 
Takano, 1995a). Other peptides derived from β-CN released after milk fermentation with 154 
Enterococcus faecalis, with sequences LHLPLP and HLPLP, have also shown 155 
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antihypertensive effect in this rat model (Miguel, Recio, Ramos, Delgado, & Aleixandre, 156 
2006; Quirós et al., 2007). In recent studies, fermented milks with Lactococcus lactis 157 
NRRLB-50 571 and NRRLB-50 572 have presented important SBP, diastolic blood pressure 158 
(DBP), and heart rate-lowering effects in SHR (Rodríguez-Figueroa, González-Córdova, 159 
Torres-Llanez, Garcia, & Vallejo-Cordoba, 2012;  Rodríguez-Figueroa, González-Córdova, 160 
Astiazaran-Garcia, Hernández-Mendoza & Vallejo-Cordoba, 2013).    161 
Most of the human intervention studies have focused on the tripeptides IPP and VPP. 162 
Two meta-analyses performed with the published data of 17 and 12 clinical trials have been 163 
reported by Pripp (2008) and Xu, Qin, Wang, Li, & Chang (2008), respectively. These meta-164 
analyses have reported an average decrease in SBP of 5.1 and 4.8 mm of Hg, respectively. A 165 
recent meta-analysis carried out with 28 clinical trials has reported a mean reduction of SBP 166 
of 1.66 mm of Hg (Qin et al., 2013). However, other clinical trials have reached controversial 167 
results. In fact, Engberink et al. (2008) and Usinger, Jensen, Flambard, Linnneberg, and Ibsen 168 
(2010) did not find an effect on human blood pressure in Dutch and Danish subjects when 169 
they daily consumed fermented milks containing peptides IPP and VPP. Recently, the meta-170 
analysis of Cicero, Gerocarni, Laghi, and Borghi (2011), which included 18 trials, has 171 
reported that IPP and VPP reduce SBP in Asian subjects while this effect was lower in 172 
Caucasian individuals. Moreover, Cicero, Aubin, Azais-Braesco, & Borghi (2013) have found 173 
that these peptides can significantly decrease SBP in European subjects, as previously shown 174 
in Japanese subjects, although the effects were more noteworthy in middle-age adults. These 175 
findings suggest that genetics and/or dietary patterns might exert an important influence on 176 
the antihypertensive effects of peptides IPP and VPP, with further studies being needed to 177 
confirm this hypothesis. Moreover, the European Food Safety Authority (EFSA) Panel on 178 
Dietetic Products, Nutrition and Allergies (NDA) (2009) has concluded that the evidence 179 
presented to date on the antihypertensive effects of peptides VPP and IPP is insufficient to 180 
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establish a cause/effect relationship between the consumption of these peptides and the 181 
maintenance of normal blood pressure, and therefore, further studies are required. 182 
Other milk protein derived hydrolysates and peptides have been tested in clinical 183 
trials. The consumption of a whey protein hydrolysate for 6 weeks resulted in a reduction of 184 
SBP and DBP of hypertensive subjects, although peptides responsible for the observed effects 185 
have not been identified yet (Pins & Keenan, 2006). More recently, it was reported that 186 
peptides RYLGY and AYFYPEL could also reduce blood pressure in hypertensive humans 187 
(Recio et al., 2011). A yogurt enriched with these peptides was administrated to 71 188 
hypertensive subjects (divided in placebo and active substances groups), and 50 normotensive 189 
volunteers that only received active substance. After 6 weeks of consumption, the 190 
hypertensive patients showed a notable reduction in their SBP, while no significant changes in 191 
blood pressure were detected in both the placebo and the normotensive groups.  192 
 193 
3.1.2. Anti-inflammatory and antioxidant properties of peptides 194 
Chronic inflammation is involved in many age-related diseases, such as 195 
atherosclerosis, vascular diseases, arthritis, cancer, diabetes, osteoporosis, dementia, obesity, 196 
and metabolic syndrome (Yu & Chung, 2006). Different cytokines play a pivotal role as 197 
mediators in the production of biomarkers implied in the progression of inflammation and the 198 
endothelial dysfunction. The down-regulation of these cytokines by food components, 199 
including peptides, may retard or alleviate inflammation, thus exerting beneficial effects 200 
against cardiovascular diseases (Tompa et al., 2010). To date, only the commercial peptide 201 
NOP-47, derived from whey, has demonstrated in a clinical study to enhance the vascular 202 
function by modulating glucose levels and biomarkers of inflammation and oxidative stress in 203 
healthy individuals (Ballard et al., 2009).  204 
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In vitro, a preliminary study using lipopolysaccharide (LPS)-stimulated murine 205 
peritoneal macrophages suggests the potential role of a yak CN hydrolysate with alcalase to 206 
prevent inflammation-related disorders because of its ability to reduce the secretion of pro-207 
inflammatory cytokines, and the production of nitric oxide (NO). Also, this hydrolysate has 208 
demonstrated to exert radical scavenging activity that might contribute to its beneficial 209 
properties (Mao, Cheng, Wang, & Wu, 2011).  210 
Obesity is accompanied by low-grade chronic inflammation in different tissues such as 211 
adipose tissue, liver, pancreas, muscle and brain (Troncon Rosa, Zulet, Marchini, & Martínez, 212 
2012). The inflammatory response associated to obesity provokes the activation of cytokines 213 
and transcriptional factors, and the penetration of macrophages in the adipose tissue, resulting 214 
in an unresolved response associated with insulin resistance, endothelial dysfunction and 215 
subsequent cardiovascular disorders (Chung et al., 2009). Dietary interventions targeted at 216 
reducing adipose tissue inflammation can be a valuable alternative for improving the general 217 
metabolic profile (Siriwardhana et al., 2013). However, studies conducted by Pal & Ellis 218 
(2010, 2011) did not observe significant reductions in inflammatory biomarkers of overweight 219 
and obese subjects after neither acute nor chronic supplementation with sodium caseinate or 220 
WPI compared to control. These results are in agreement with those reported by Lee, Skurk, 221 
Hennig, & Hauner (2007) which did not show any significant difference after administration 222 
of skimmed milk to mild hypertensive subjects. These authors suggested that potential 223 
bioactive peptides could be hydrolysed by intestinal or plasma peptidases, losing their anti-224 
inflammatory activity. The lack of concluding findings makes difficult guaranteeing the anti-225 
inflammatory activity of peptides derived from CN or whey proteins, and more studies are 226 
needed to confirm it.  227 
Oxidative stress is another responsible factor for the initiation or evolution of 228 
cardiovascular diseases. Natural antioxidants provide additional benefits to the endogenous 229 
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defense strategies in the battle against oxidative stress (Erdmann et al., 2008). Food derived 230 
peptides have shown to be potent antioxidants without important side effects (Sarmadi & 231 
Ismail, 2010), with milk proteins being one of the most frequently studied sources. To date, 232 
many antioxidant peptides derived from both CN and whey proteins have been characterised 233 
by in vitro chemical assays (Pihlanto, 2006; Power, Jakeman, & Fitzgerald, 2013). These 234 
assays are restricted because of their limited similarity to physiological conditions, and further 235 
studies are needed to confirm the demonstrated effects. In the last years, cell cultures are 236 
being used to assess the potential health effects of antioxidant milk-derived hydrolysates 237 
and/or peptides. These models are useful because they allow evaluation of additional factors 238 
such as peptide bioavailability and metabolism besides biological activity. However, to our 239 
knowledge, no cell culture experiments demonstrating the antioxidant activity on the 240 
cardiovascular system have been conducted.  241 
 The results of animal experiments and human trials suggest that fermented milk 242 
products may exert antioxidant effects associated to cardiovascular benefits. Zommara, 243 
Tougo, Sakanao, and Imaizumi (1998) found that fermented milk produces an anti-244 
peroxidative action on rats fed a vitamin-E deficient diet. Moreover, the consumption of 245 
fermented goat milk by healthy individuals improved the total plasma antioxidant activity, 246 
lowered the levels of oxidized low density lipoprotein, isoprostanes and the glutathione redox 247 
ratio, and prolonged the resistance of the lipoprotein fraction to oxidation, resulting in the 248 
improvement of the anti-atherogenicity (Kullisaar et al., 2003). Although the compounds 249 
responsible for these effects have not been identified yet, peptides released during milk 250 
fermentation might have a key function. Consequently, further studies elucidating the role of 251 
antioxidant peptides in the protective activity of fermented milks on the cardiovascular system 252 
are needed.  253 
 254 
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3.1.3. Hypocholesterolemic peptides 255 
Diet plays a key role in plasma lipids profile, and consequently it is used as a strategy 256 
to prevent or decrease the incidence of cardiovascular diseases (Erdmann et al., 2008). It was 257 
observed that whey protein displayed a hypocholesterolemic effect in rats after the ingestion 258 
of cholesterol free or cholesterol-enriched diets compared to CN or soybean proteins enriched 259 
diets (Nagaoka, Kanamaru, & Kuzuya, 1991; Nagaoka, Kanamaru, Kuzuya, Kojima, & 260 
Kuwata, 1992). This effect was confirmed when a tryptic hydrolysate of β-lactoglobulin (β-261 
Lg) was administered to rats fed a diet rich in cholesterol. A notable reduction in the 262 
cholesterol level as well as an increase of the high density lipoproteins-cholesterol content, 263 
and of the excretion of fecal steroid was observed (Nagaoka et al., 2001). 264 
A peptide called lactostatin, IIAEK, corresponding to fragment f(71-75) of β-Lg, 265 
obtained from its tryptic hydrolysate, showed hypocholesterolemic activity in rats, being this 266 
effect higher than that showed by β-sitosterol (Nagaoka et al., 2001). Another β-Lg derived 267 
peptide, β-lactotensin (HIRL), obtained by hydrolysis with chymotrypsin, decreased total 268 
cholesterol and low density lipoproteins plus very low density lipoproteins-cholesterol content 269 
in mice fed a cholesterol-enriched diet (Yamauchi, Ohinata, & Yoshikawa, 2003). The exact 270 
mechanisms involved in the hypocholesterolemic activity of these peptides have not been 271 
elucidated yet, but the preliminary results suggested that the amino acid composition may 272 
play a key influence (Erdmann et al., 2008). However, more studies are clearly needed to 273 
confirm the results, especially in humans determining the exact mechanism of this action. 274 
 275 
3.2. Effects on intestinal health 276 
The intestine is an organ responsible for nutrient absorption, barrier functions, signal 277 
recognition, and the production of endogenous active molecules. Many physiological actions 278 
are known to be regulated by hormones or cytokines, but substances contained in the diet are 279 
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also thought to play a role as modulators of intestinal functions. Peptides derived from milk 280 
proteins are a group of substances with potential effects at gastrointestinal level through 281 
different mechanisms of action. They have been shown to exert protective actions on 282 
intestinal mucus, modulatory effects of mineral absorption, and anti-inflammatory, 283 
antidiabetic, and satiating activities.  284 
 285 
3.2.1. Protective effect on the gut mucosa 286 
 The protective properties of the gastrointestinal mucus gel are attributed to its 287 
principal component, mucins, high molecular weight glycoproteins secreted by goblet cells. 288 
Disruption of the structure of this mucus has important physiological implications (Corfield et 289 
al., 2000; Linden, Sutton, Karlsson, Korolik, & McGuckin, 2008), and strong evidence was 290 
reported when spontaneous colitis and colon cancer were developed in mice genetically 291 
deficient in the mucin gene Muc2 (van der Sluis et al., 2006; Velcich et al., 2002). 292 
Although intestinal epithelial cells functions are usually controlled by endogenous 293 
agents, it is worth mentioning that these cells come into continuous contact with high 294 
concentrations of food components and substances along the gut luminal surface; hence, they 295 
might be also regulated by external factors, such as nutrients (Gibson & Muir, 2005; 296 
Moughan et al., 2007). Interestingly, some dietary compounds have proven capacity to 297 
positively influence the protective properties of the mucus gel layer (Montagne, Piel, & 298 
Lalles, 2004). Dairy proteins, hydrolysates, and peptides have been demonstrated to modify 299 
the dynamics of mucus mainly via influencing the mucin secretion and expression, and the 300 
number of globet cells. The published studies showing evidence of these bioactivities in ex-301 
vivo, in vitro and/or in vivo assays are summarised in Table 2. 302 
In the first studies carried out using an ex-vivo preparation of rat jejunum, CN and α-303 
lactalbumin (α-La) hydrolysates evoked an increase in the mucin secretion, while native CN 304 
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did not produce any effect (Claustre et al., 2002; Trompette et al., 2003). The peptide β-305 
casomorphin 7, derived from β-CN, showed a strong rise in the mucin glycoprotein secretion. 306 
Since the observed effects were abolished by pre-treatment with opioid antagonist naloxone, 307 
it has been suggested that the activity might be mediated by interaction with opioid receptors. 308 
Additionally, Zoghbi et al. (2006) demonstrated that β-casomorphin 7 significantly enhanced 309 
the mucin secretion and stimulated the expression of mucin Muc2 and Muc3 genes in rat 310 
intestinal cells DHE, and MUC5AC gen in human intestinal cells HT29-MTX. Recently, a 311 
whey protein hydrolysate rich in β-Lg-derived peptides was found to induce mucin secretion 312 
and MUC5AC gene expression in HT29-MTX cells (Martínez-Maqueda, Miralles, Ramos, & 313 
Recio, 2013a). Among the peptides contained in this hydrolysate, sequence β-lactorphin was 314 
identified as the major responsible for the observed effects. Cells exposed to β-lactorphin 315 
increased their mucin synthesis, whereas no significant differences were observed in the 316 
MUC5AC expression analysis (Martínez-Maqueda et al., 2013a). The stimulatory effect of a 317 
CN hydrolysate has been also assessed in HT29-MTX cells by Martínez-Maqueda, Miralles, 318 
Cruz-Huerta, & Recio (2013b). The hydrolysate and two αs1-CN-peptides contained in it, 319 
promoted the mucin output via inducing mucin-like glycoprotein secretion and MUC5AC 320 
over-expression. Similarly, Plaisancié et al. (2013) have evaluated the impact of a total 321 
peptide pool from commercial yogurt in HT29-MTX cells, observing an increase of the 322 
secreted mucin, and the mRNA levels of MUC2 and MUC4 genes. The β-CN fragment f(94-323 
123) was suggested to be responsible for the reported bioactivities after evaluating its effects 324 
in intestinal cells and in rats. Oral administration of this peptide to rats yielded an increase in 325 
the globet cells counts, modified Muc2 and Muc4 mRNA expression, and ultimately 326 
improved gut mucosa protection by enhancing crypts containing Paneth cells and increasing 327 
the number of rat defensin 5 and lysozyme (LZ) mRNA transcripts in the rat small intestine 328 
(Plaisancié et al., 2013).  329 
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Other in vivo studies have also pointed to the regulation of the protective mucus layer 330 
by dairy proteins and their degradation products. A diet containing a CN hydrolysate as the 331 
exclusive source of nitrogen was given to rats in which enhancements in the ileal endogenous 332 
nitrogen flow and in the expression of Muc3 in the small intestine, and Muc4 in the colon 333 
were observed (Han, Deglaire, Sengupta, & Moughan, 2008). In the study of Sprong, 334 
Schonewille, and van der Meer (2010), the protective effect of cheese whey protein was 335 
examined in the dextran sulfate sodium (DSS)-induced model of rat colitis. After seven days 336 
of DSS consumption, rats fed the cheese whey protein diet showed lower levels for both 337 
mucosal and luminal markers of colitis. Although fecal mucin excretion was higher, 338 
expression of Muc2 in the colon was not statistically different from controls. Incorporation of 339 
cheese whey protein to the diet also resulted in an increase of the counts of protective 340 
microbiota species. Interestingly, one group of rats fed a diet consisting in CN with 341 
threonine/cysteine supplementation was included in the study, and the observed protection 342 
against DSS-induced colitis was similar to the rats fed the cheese whey protein diet (Sprong et 343 
al., 2010). It was therefore suggested that reported beneficial effects of cheese whey protein 344 
might be due to its high threonine and cysteine content. In this context, availability of specific 345 
amino acids like threonine, cysteine, proline and serine has been shown to be important to 346 
increase the number of Muc2-containing globet cells, up-regulate the mucin synthesis, and 347 
restore the bowel microbiota, thus helping colonic defenses and mucosal healing in DSS-348 
treated rats (Faure et al., 2006).  349 
 350 
3.2.2. Modulatory peptides of mineral absorption 351 
Mineral deficiencies are the most important nutritional problems worlwide, with the 352 
iron deficiency being the most common. This disorder happens when the mineral ingestion 353 
from diet does not meet a daily need of minerals. In this context, the mineral fortification is 354 
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one of the best and most common strategies to prevent this deficiency (Zimmermann & 355 
Hurrell, 2007). It has been proposed that the phosphorylated regions released from CN during 356 
digestion, CPPs, could increase mineral solubility at intestinal pH, modulating its 357 
bioavailability (Meisel & Fitzgerald, 2003). Several authors have demonstrated the release of 358 
CPPs in rats and minipigs after the ingestion of CN (Kasai, Iwasaki, Tanaka, & Kiriyama, 359 
1995; Meisel & Frister, 1988, 1989; Naito & Suzuki, 1972, 1974; Sato, Noguchi, & Naito, 360 
1986; Sato, Shindo, Gunshin, Noguchi, & Naito, 1991). In humans, the liberation of CPPs has 361 
been reported after consumption of milk, yogurt, and CN (Boutrou et al., 2013; Chabance et 362 
al., 1998; Meisel et al., 2003). Also, CPPs have been demonstrated to resist further 363 
degradation by digestive enzymes and enteric bacteria in both rats and humans (Brommage, 364 
Juillerat, & Jost, 1991; Hirayama, Toyota, Hidaka, & Naito, 1992; Kasai et al., 1995; Meisel 365 
et al., 2003). Regarding the in vivo studies with CPP preparations, several authors have 366 
reported an increase of the soluble calcium concentration in the intestine of rats due to CPPs 367 
released from CN contained in the diet, which should improve the absorption of this mineral 368 
(Kitts, Yuan, Nagasawa, & Moriyama, 1992; Lee, Noguchi, & Naito, 1979, 1980, 1983; Sato, 369 
Noguchi, & Naito, 1983; Sato et al., 1986). However, the results of studies on the influence of 370 
CPPs upon calcium absorption in humans and animal models are controversial.  371 
The addition of a pool of CPPs to aqueous solutions and infant foods containing 372 
phytate increased calcium absorption in rat pups after gastric intubation, being able to 373 
overcome the negative effect of phytate on its absorption (Hansen, Sandström, & Lönnerdal, 374 
1996). In agreement with this result, in rats fed an isolated soy protein-based diet 375 
supplemented with CPPs and calcium, an increase of calcium absorption was reported, 376 
although the effect was not dose dependent (Saito, Lee, & Kimura, 1998). In contrast, diet 377 
supplementation with CPPs and calcium did not improve calcium absorption in growing pigs 378 
fed a soy-based diet (Pointillart & Guéguen, 1989), in rats fed a whey protein-based diet 379 
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(Brommage et al., 1991; Kopra, Scholz-Ahrens, & Barth, 1992; Scholz-Ahrens, Kopra, & 380 
Barth, 1990), or in rats fed an experimental diet containing mainly egg albumin, corn starch, 381 
and glucose (Tsuchita, Goto, Yonehara, & Kuwata, 1995; Bennett et al., 2000). In 382 
ovariectomized rats, used as a postmenopausal bone loss model, calcium absorption was 383 
enhanced in the first three days when CPPs derived from β-CN and calcium (at higher doses) 384 
were supplemented (Tsuchita, Sekiguchi, Kuwata, Igarashi, & Ezawa, 1993). No effects of 385 
CPPs upon calcium absorption was observed in rats after administration by gastric intubation 386 
of non-fortified milk while an increase was observed when administered milk was fortified 387 
with calcium (Mora-Gutierrez, Farrell, Attaie, McWhinney, & Wang, 2007; Tsuchita, Suzuki, 388 
& Kuwata, 2001). Using a ligated duodenal loop technique, CPPs increased calcium 389 
absorption in rachitic and normal chicks (Mykkänen & Wasserman, 1980), and rats (Kitts et 390 
al., 1992; Sato et al., 1986). These results are in disagreement with the observations of Yuan 391 
and Kitts (1991) in the same model, who did not observe any difference on calcium 392 
absorption after addition of CPPs to CN or soybean enriched diets. The controversial results 393 
obtained in the above mentioned studies could be caused by several factors influencing the 394 
effect of CPPs, such as the animal model, physiological status of the individuals, type of diet 395 
and its calcium or vitamin D content, source and composition of CPPs, and the length of the 396 
assay, among others. 397 
In humans, an increase of calcium absorption has been shown due to the addition of 398 
CPPs to rice-based cereal, although the effect was not observed after addition to whole-grain 399 
cereal or to three different meals with different calcium and phytate contents (Hansen, 400 
Sandström, Jensen, & Sorensen, 1997a, b). It has been not observed influence of CPPs upon 401 
calcium bioavailability after their ingestion with milk (López-Huertas et al., 2006; Narva, 402 
Kärkkäinen, Poussa, Lamberg-Allardt, & Korpela, 2003) or with a drink of calcium lactate 403 
(Teucher et al., 2006). In contrast, Heany, Saito, & Orimo (1994) showed a positive role of 404 
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CPPs in postmenopausal women with low calcium absorption capacity, despite the fact that 405 
this effect was not observed in women with normal absorption capacity of this mineral. 406 
CPPs bound to calcium salts have been also found to be useful to remineralize the 407 
teeth of mammals, displaying anticariogenic effects when added to dentifrices, oral care 408 
products, chewing gum or other confectionery foods (Luo & Wong, 2004). In human trials, 409 
synthetic nanocomplexes of CPPs and calcium salts incorporated in mouth rinses and sugar-410 
free chewing gums have been proven to be potential anticariogenic agents (Reynolds, Cai, 411 
Shen, & Walker, 2003). 412 
Concerning the iron bioavailability, a positive influence of CPPs on this parameter has 413 
been reported, reflected in an increase in the hemoglobin and hematocrit levels, as well as in 414 
the iron liver storage when iron deficient rats were supplemented with iron and hydrolysed β-415 
CN or β-CN fragment f(1-25)4P (Aït-Oukhatar et al., 1997, 1999). Likewise, the blood iron 416 
levels were increased in rats after ingestion of iron bound to hydrolysed CN (Chaud et al., 417 
2002). These results were confirmed using a perfused rat intestinal model loop system, in 418 
which the iron bound to β-CN f(1-25)4P increased the absorption of this mineral in iron 419 
deficient and non-iron deficient rats (Aït-Oukhatar et al., 2002; Ani-Kibangou et al., 2005; 420 
Bouhallab et al., 2002; Pèrés et al., 1997, 1999a, b). In addition, diverse fractions of CPPs 421 
exerted different effects on iron absorption, being this effect higher when the iron was bound 422 
to β-CN fractions than to αs-CN fractions (Bouhallab et al., 2002; Kibangou et al., 2005), 423 
suggesting the influence of the structural characteristics and conformations of CPPs on their 424 
capacity to improve the iron bioavailability. 425 
In humans, the effect of CPPs on iron bioavailability is controversial. Whereas 426 
Hurrell, Lynch, Trinidad, Dassenko, and Cook (1989) reported an improvement of iron 427 
absorption after the intake of hydrolysed CN, Aït-Oukhatar et al. (2002) did not observe any 428 
effect after the ingestion of iron bound to β-CN f(1-25). In vivo studies with other minerals, 429 
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such as zinc, have also found variable results. Hansen et al. (1996) reported an increased zinc 430 
absorption in rat pups after the addition of CPPs to aqueous solutions and infant foods 431 
containing phytate, avoiding the negative effect of this compound on zinc bioavailability. 432 
However, no effect was reported from soybean protein based diet containing CPPs in rats 433 
(Matsui, Okumura, & Yano, 2002). As observed for calcium, zinc absorption was reported to 434 
increase when CPPs were added to rice-based cereal. However, no effects were observed 435 
when CPPs were added to whole-grain cereal or three different meals with different calcium 436 
and phytate contents (Hansen et al., 1997a, b). These results indicate that the effects of CPPs 437 
can be influenced by factors, such as the food matrix, i.e., liquid or solid diet, as well as the 438 
phytate content (Miquel & Farré, 2007). 439 
 440 
3.2.3. Anti-inflammatory peptides at gastrointestinal level 441 
Inflammatory bowel disease is a chronic and degenerative condition comprising a 442 
group of disorders, being the ulcerative colitis and Crohn’s disease the most relevant both in 443 
incidence and prevalence. Although the etiology of this disease remains unknown, it has been 444 
demonstrated that genetic, immunological, environmental, and lifestyle factors are implied 445 
(Bernstein et al., 2009). Currently, inflammatory bowel disease is mainly treated with drugs 446 
that suppress the immune system. However, the multiple adverse effects shown by these 447 
drugs have made that their use is limited and selective to a small number of patients. To avoid 448 
these limitations, new and natural treatments without side effects are being searched and 449 
developed (Sánchez de Medina et al., 2010). The most extensively studied peptide for its 450 
activity against intestinal inflammation is the bovine caseinomacropeptide (CMP). In recent 451 
years, different animal models of intestinal inflammation have been used to provide evidence 452 
on the anti-inflammatory effect of CMP at gastrointestinal level. The activity of this peptide 453 
in mice with colitis and ileitis induced by 2,4,6-trinitrobenzene sulphonic acid (TNBS), a 454 
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model that shares important similarities with human Crohn’s disease has been established 455 
(Daddaoua et al., 2005; Requena et al., 2008). Recently, the effects have been assessed in the 456 
DSS-induced model of rat colitis (López Posadas et al., 2010). These studies also evaluated 457 
the mechanism of action of CMP indicating that it mainly acts on the inflammatory/immune 458 
response by the activation of macrophages, favoring the differentiation of regulatory T cells 459 
and limiting the activation of T helper 1 cells (Sánchez de Medina et al., 2010). 460 
Preliminary studies have shown the anti-inflammatory effect of β-CN hydrolysates by 461 
Lactobacillus delbrueckii ssp. lactis CRL581 in a murine TNBS-induced colitis model 462 
(Espeche Turbay, de Moreno de LeBlanc, Perdigón, Savoy de Giori, & Hebert, 2012). Thus, 463 
these results suggest that other milk peptides in addition to CMP might act as protective 464 
agents on intestinal inflammation, and further studies focused on the identification of 465 
potentially responsible sequences, and the evaluation of their mechanism of action should be 466 
designed. 467 
 468 
 3.2.4. Peptides against type 2 diabetes 469 
Ingestion of a meal provokes the secretion, at gastrointestinal level, of incretins 470 
hormones, such as glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic 471 
polypeptide (GIP). These hormones are involved in the modulation of gut motility, secretion 472 
of gastric and pancreatic enzymes, nutrient absorption, and stimulation of the insulin secretion 473 
from the pancreas that allows the disposal of the absorbed glucose (Drucker & Nauck, 2006). 474 
Type 2 diabetes, representing 90–95% of the diagnosed cases of diabetes, is characterised by 475 
multiple pathophysiologic defects including progressive dysfunction of pancreatic cells, 476 
insulin resistance, and increased production of hepatic glucose (Bharatam, Patel, Adane, 477 
Mittal, & Sundriyal, 2007). It has been demonstrated that continuous intravenous 478 
administration of GLP-1 normalizes blood glucose levels in diabetic patients (Nauck et al., 479 
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1993). However, the rapid degradation of this hormone by the enzyme dipeptidyl-peptidase 480 
IV (DPP-IV) makes this strategy for the type 2 diabetes treatment unfeasible. Currently, 481 
incretin-based therapies include a combination of GLP-1 analogues resistant to DPP-IV 482 
action, and orally bioavailable DPP-IV inhibitors (Fadini & Avogaro, 2011).  483 
Diet supplementation with whey protein has been demonstrated, by preclinical and 484 
clinical studies, to potentiate insulin release and ameliorate postprandial glucose control in 485 
both healthy and type 2 diabetic subjects (Sousa et al., 2012). Initially, it was suggested that 486 
these effects were due to its rapid digestion and the consequent fast increase of the levels of 487 
different amino acids in plasma (Luhovyy, Akhavan, & Anderson, 2007). However, the intake 488 
of free amino acid mixtures did not produce the same effects (Nilsson, Holst, & Bjorck, 489 
2007). Recently, it has been hypothesised that peptides released from whey proteins during 490 
their transit through gastrointestinal tract might be responsible for the postmeal glycaemic 491 
response produced after whey intake (Akhavan, Luhovyy, Brown, Cho, & Anderson, 2010). 492 
Even the acute ingestion of a whey protein hydrolysate by rats resulted in a higher transient 493 
leucine response with a sequential increase in insulin (Toedebusch et al., 2012). A recent 494 
study has demonstrated the dose-dependent insulinotropic effect of whey protein hydrolysates 495 
in a cell-based co-culture approach using pancreatic BRIN-BD11 beta cells and Caco-2 cells 496 
monolayers (Gaudel et al., 2013). These authors confirmed these effects in obese (ob/ob) 497 
mice, observing, after the oral administration of those hydrolysates, an improvement of blood 498 
glucose clearance, reduction of hyperinsulinemia, and restoration of the pancreatic islet 499 
capacity to secrete insulin in response to glucose. 500 
In addition, a significant reduction of DPP-IV activity was observed in the proximal 501 
small bowel of rodents fed whey proteins (Gunnarsson et al., 2006), suggesting that peptides 502 
released from these proteins might exert DPP-IV inhibitory effects at intestinal level. Recent 503 
studies have demonstrated the in vitro DPP-IV inhibitory activity of hydrolysates derived 504 
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from whey proteins, and peptides contained in these hydrolysates, and potentially responsible 505 
for the observed effects have been identified (Nongonierma & Fitzgerald, 2013). Among 506 
these peptides, sequences IPA (β-lactosin) and IPAVF, derived from β-Lg are amongst the 507 
most effective DPP-IV inhibitory peptides described to date (Silveira, Martínez-Maqueda, 508 
Recio, & Hernández-Ledesma, 2013; Tulipano, Sibilia, Caroli, & Cocchi, 2011). A β-Lg-509 
derived peptide, with the sequence VAGTWY, presented hypoglycemic effects in the oral 510 
glucose tolerance test in mice (Uchida, Ohshiba, & Mogami, 2011). This in vivo effect has 511 
been also demonstrated for the peptide LPQNIPPL, a CN-derived fragment described as DPP-512 
IV inhibitor (Uenishi, Kabuki, Seto, Serizawa, & Nakajima, 2012). In fact, a recent in silico 513 
study has shown that both CN and whey proteins serve as precursors of DPP-IV inhibitory 514 
peptides because of the high number of fragments contained within them that match DPP-IV 515 
inhibitory sequences described in the literature (Lacroix & Li-Chan, 2012).  516 
 517 
3.2.5. Effect on satiety 518 
It is recognized that protein is the most satiating macronutrient of food (Fromentin et 519 
al., 2012). Although it is not clear if the source of protein can influence this satiating effect, 520 
the consumption of dairy foods and calcium has been recommended in several diets aiming 521 
the regulation of the body weight. Several clinical studies have proposed a certain satiating 522 
effect for dairy products. For instance, in a 6-month trial with an energy-restricted diet, the 523 
group receiving milk supplementation showed a decreased desire to eat and hunger vs. the 524 
placebo group, although no differences in the level of ghrelin or leptin were found (Gilbert et 525 
al., 2011). In a recent study with 49 overweight and obese adults, the high-dairy group had 526 
similar weight loss than the low-dairy group, but high-dairy group showed slightly higher 527 
peptide YY concentrations in plasma and enhanced sensation of satisfaction (Jones et al., 528 
2013). 529 
 
 
23
The mechanisms of action of different protein types on satiety are still under 530 
investigation, but it has been proposed that it could be related to a slowdown of the gastric 531 
emptying, an increase in brain amino acids, or the presence of specific peptides or amino 532 
acids. In this respect, it has been highlighted that in animal or human trials, diet has to be well 533 
equilibrated in its essential amino acid content in order to prevent depression in food intake 534 
due to conditioned food aversion (Fromentin et al., 2012). In particular, it has been proposed 535 
that whey proteins contribute to short term appetite suppression, with this effect being higher 536 
than that obtained with CN, soy protein and egg albumin (Anderson, Tecimer, Shah, & Zafar, 537 
2004). This effect can be attributed to the high content in branched-chain amino acids 538 
(mainly, L-leucine), the presence of certain peptides, such as CMP, or it can be mediated by 539 
the release of satiety hormones (cholecystokinin, GLP-1, GIP, peptide YY or ghrelin). A 540 
review that summarizes the evidence built in animal and human trials on the effect of whey 541 
protein consumption on satiety and intake regulatory mechanisms has been previously 542 
published (Luhovy et al., 2007). Later reports have compared the effect of whey protein and a 543 
whey protein hydrolysate, when consumed before a meal, on glucose and insulin levels and 544 
pre- and post-meal satiety. Interestingly, it was found that the whey protein, but not the whey 545 
protein hydrolysate, reduced post-meal blood glucose and insulin concentrations in a dose-546 
dependent manner, and diminished food intake (Akhavan et al., 2010). Therefore, it seems 547 
relevant the form in which the protein is ingested, or in other words, the peptides that reach 548 
the gut during gastrointestinal digestion of whey proteins. Peptide composition and 549 
characterisation of hydrolysates is definitive in this kind of studies in order to extract cause-550 
effect conclusions. Other studies have confirmed that whey proteins enhance satiety in 551 
humans in a short time period of time compared to carbohydrates but the effect could not be 552 
attributed to CMP since same effect was achieved with a WPI without CMP (Lam, Moughan, 553 
Awati, & Morton, 2009). Similarly, in a double-blind acute study with 20 overweight/obese 554 
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males, no differences were found on plasma cholecystokinin levels or subjective satiety after 555 
ingestion of CMP with different glycosylation levels (Keogh et al., 2010). However, a 556 
positive effect was shown in a study with individuals with phenylketonuria where the 557 
consumption of CMP at breakfast was compared with an amino acid-based formula. Lower 558 
postpandrial ghrelin levels after breakfast containing CMP associated with a greater feeling of 559 
fullness were found (MacLeod, Clayton, van Calcar, & Ney, 2010). Consequently, more work 560 
is needed to confirm the effect or certain whey components on satiety, and to elucidate the 561 
mechanism of action implicated in the activity of the whey protein fraction. Finally, it has 562 
been pointed out that the difference in satiety by various proteins can be also influenced by 563 
the physical properties of food in the gut, and factors, such as, viscosity, or clotting of 564 
proteins in the gut play an important role. For instance, in a comparative study with whey 565 
protein drinks and alginate-based drinks with different viscosities and protein contents, it was 566 
found that subjects reported reduced hunger with protein drinks with higher viscosity 567 
independently of the protein content, suggesting that viscosity can exert a higher effect than 568 
protein concentration (Solah et al., 2010). 569 
Concerning the CN fraction of milk, it is known that peripheral opioid and 570 
cholecystokinin receptors are activated by ingestion of CN, and blocking receptors with 571 
antagonists reduces their effect on food intake (Froetschel, Azain, Edwards, Barb, & Amos, 572 
2001; Pupovac & Anderson, 2002). Therefore, the presence of peptides able to interact with 573 
these receptors will determine the activity of CN hydrolysates. Because the composition of 574 
the CN hydrolysates varies with the hydrolysis process, peptidomic characterization of the 575 
products is essential. 576 
In a comparative study of CN and whey on gastrointestinal hormone secretion and 577 
appetite, it was found a greater subjective satiety after the whey load. Whey also produced a 578 
higher increase in postprandial plasma amino acid concentration, and higher levels of 579 
 
 
25
cholecystokinin, GLP-1 and GIP than CN. These results emphasise the importance of the type 580 
of protein, and confirm that post-absorptive increases in plasma amino acids and 581 
gastrointestinal hormones are involved in the appetite response (Hall, Millward, Long, & 582 
Morgan, 2003). 583 
 584 
3.3. Effects on body defences 585 
Apart from their nutritional value, milk proteins are able to exert physiological 586 
activities aiming to protect the newborn mammal. Furthermore, throughout the course of 587 
digestion of milk, bioactive peptides are released from consumed proteins. These peptides 588 
may possess not only immunomodulatory, but also antimicrobial and antiproliferative 589 
properties that help improving the defence system of the neonate. 590 
  591 
3.3.1. Antimicrobial peptides 592 
The antimicrobial activities of milk protein-derived peptides are very diverse, ranging 593 
from those with a prebiotic effect, peptides with the ability to prevent the attachment or 594 
invasion of pathogen microorganisms, to peptides killing or inhibiting the growth of 595 
microorganims. This section will refer to this latter group of peptides with special emphasis 596 
on those peptides with antibacterial activity. The antiviral activity of dairy proteins, 597 
modifications thereof, and derived peptides has been reviewed by different authors (Pan et al., 598 
2006; Berlutti et al., 2011). 599 
Milk-derived antimicrobial peptides are characterised by a highly positively charged 600 
sequence and certain amphiphilic character. It has been proposed that the net positive charge 601 
will aid binding to negatively charged bacterial membranes and the amphiphilic character will 602 
help membrane disruption. Some peptides, like LFcin and lactoferrampin, contain also a 603 
hydrophobic region with a tryptophan residue, which is involved in membrane insertion 604 
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(Schiffer, Chang, & Stevens, 1992). However, recent reports have also described the activity 605 
of anionic peptides-enriched extracts from Cheddar cheese against Listeria monocytogenes 606 
(Demers-Mathieu et al., 2013a). The origin and activity of some of the most relevant 607 
antibacterial peptides derived from milk proteins are summarised in Table 3. 608 
The antimicrobial peptides that have received most attention in the last two decades 609 
are derived from lactoferrin (LF). Hydrolysis of bovine LF with pepsin generates several 610 
protein fragments with antibacterial activity. Among them, fragment f(17-41/42), known as 611 
LFcin (Bellamy et al., 1992), is one of the most potent with a broad spectrum against Gram-612 
positive and Gram-negative bacteria; but also other active fragments from the N-lobe of the 613 
protein, i.e., f(267-285), f(267-288), and f(277-288), are released by the action of this enzyme 614 
(Recio & Visser, 1999b). A peptide from this region of the protein, f(268-288), called 615 
lactoferrampin, was later chemically synthesized, and it has demonstrated activity against 616 
Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa (van der Kraan et al., 2004). 617 
Recently, it has been shown that chimerization of LFcin and lactoferrampin increases activity 618 
against various microorganisms, such as Candida albicans, and Burkholderia pseudomallei 619 
(Bolscher, Nazmi, van Marle, van 't Hof, & Veerman, 2012; Puknun et al., 2013). 620 
Digestion of the major bovine whey proteins, β-Lg and α-La, with trypsin and 621 
chymotrypsin, respectively, releases peptides with moderate activity against Gram-positive 622 
bacteria (Pellegrini, Dettling, Thomas, & Hunziker, 2001; Pellegrini, Thomas, Bramaz, 623 
Hunziker, & Von Fellenberg, 1999). Recently, Demers-Mathieu et al. (2013b) obtained an 624 
antibacterial fraction rich in anionic peptides of about 8 amino acids long by nanofiltration of 625 
a tryptic hydrolysate of a WPI. The same research group has recently demonstrated the 626 
antibacterial activity of a peptic hydrolysate of a WPI, and identified various active sequences 627 
derived from β-Lg and α-La (Theolier, Hammami, Labelle, Fliss, & Jean, 2013). 628 
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Although CN has been traditionally considered important from the nutritional point of 629 
view, it is also source of antibacterial peptides. Most relevant peptides from the CN fraction 630 
correspond to the N-terminal region of αs1-CN, several fragments from the C-terminal domain 631 
of αs2-CN and some peptides from κ-CN (Table 3). All of them are active against Gram-632 
positive and –negative bacteria, and most of them have a net positive charge. More details 633 
about the formation and the in vitro activity of these sequences have been reviewed by López-634 
Expósito & Recio (2008). 635 
Because evidence of the activity of these antibacterial fragments should be based on in 636 
vivo studies, several animal assays and few clinical trials with some of these sequences or 637 
hydrolysates have been conducted. Most of the in vivo studies have used the entire protein LF, 638 
but the observed activity can be attributed to the protein or some of the generated peptides 639 
during digestion, such as LFcin-containing fragments (Kuwata, Yip, Tomita, & Hutchens, 640 
1998a; Kuwata et al., 1998b). In vivo studies with bovine LF orally administered to mice have 641 
demonstrated protective effects against infections or septic shock, although it is not clear 642 
whether these effects can be attributed to the antibacterial activity of the protein or to 643 
immunity modulation (reviewed by van Hooijdonk, Kussendrager, & Steijns, 2000; Legrand, 644 
2012). It has been demonstrated that orally administered LF or its hydrolysate can play a role 645 
on gastrointestinal health and intestinal flora of newborns (animals or humans). For instance, 646 
a recent clinical trial with 472 infants in neonatal care showed that LF reduced fungal late-647 
onset sepsis, especially in low weight infants (Manzoni et al., 2012). Several clinical studies 648 
on the role of LF in children and neonates have been recently reviewed (Embleton, 649 
Berrington, McGuire, Stewart, & Cummings, 2013; Ochoa, Pezo, Cruz, Chea-Woo, & Cleary, 650 
2012). Other studies with LF or hydrolysates thereof have shown their in vivo protective 651 
effect in urinary tract infection (Håversen et al., 2000), and hepatic colonization of Listeria 652 
monocytogenes in mice (Lee et al., 2005). 653 
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The in vivo antibacterial activity of a αs1-CN derived antibacterial fragment, isracidin, 654 
against Listeria monocytogenes, Streptococcus pyogenes, and Staphylococcus aureus, has 655 
been demonstrated in mice. Protection of other mammals (rabbits, guinea pigs and sheeps) 656 
against this latter microorganism has been also confirmed. Later on, a tryptic CN hydrolysate 657 
that exerts antimicrobial activity through stimulation of the bacterial autolytic system was 658 
assayed in newborn calves affected with colibacillosis. The hydrolysate acted as antimicrobial 659 
but also as immunostimulant and growth promoter (Biziulevičius, Žukaité, Normantienè, 660 
Biziulevičienè, & Arestov, 2003). 661 
 662 
 3.3.2. Immunomodulatory peptides 663 
Milk contains several components essential during the neonatal development, which 664 
exhibit an important protective role against infection by modulating the immune system of the 665 
newborn. Among these components, it is found that CN, its fractions, whey proteins, LF, and 666 
their different hydrolysates show modulatory effects on the immune system in both in vitro 667 
and in vivo studies (Gauthier, Pouliot, & Saint-Sauveur, 2006; Gill, Doull, Rutherfurd, & 668 
Cross, 2000). However, most of these studies have been conducted by in vitro assays, 669 
focusing on the specific immune system, which requires an antigen-specific response (Cross 670 
& Gill, 2000). 671 
It has been reported that whey protein and its peptide fractions, obtained from 672 
hydrolysis with trypsin and chymotrypsin, modulated the immune system when they were 673 
administered to mice (Saint-Sauveur, Gauthier, Boutin, Montoni, & Fliss, 2009). These 674 
authors showed an increase in serum immunoglobulin (Ig) A levels in non-infected and 675 
Escherichia coli O157:H7 infected mice. In relation to whey proteins, it has been shown that 676 
α-La enhanced humoral immune response in mice, with this effect being higher than that 677 
shown for CN, soy or wheat diet (Bounous & Kongshavn, 1985; Bounous, Létourneau & 678 
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Kongshavn, 1983; Bounous, Shenouda, Kongshavn, & Osmond, 1985). These results were 679 
confirmed when mice were fed α-La hydrolysate (Bounous, 1981; Bounous & Kongshavn, 680 
1982).   681 
LF is considered one of the main host defenses against infections, displaying different 682 
biological activities including immunomodulation (González-Chávez, Erévalo-Gallegos, & 683 
Rascón-Cruz, 2009; Tomita, Wakabayashi, Yamauchi, Teraguchi, & Hayasawa, 2002; 684 
Wakabayashi, Yamauchi, & Takase, 2006). Thus, the ingestion of LF accelerated the 685 
improvement of immune system in immunocompromised mice (Artym, Zimecki, Paprocka, & 686 
Kruzel, 2003; Takahura et al., 2004). In this sense, it was observed a higher IgA level in the 687 
bile and intestine of mice orally immunized with cholera toxin and fed a pepsin LF 688 
hydrolysate (Miyauchi, Kaino, Shinoda, Fukuwatari, & Hayasawa, 1997), indicating that this 689 
hydrolysate improved mucosal immunity. It has to be pointed out that IgA production is the 690 
main humoral immune response given by gut-associated lymphoid tissue, which prevents the 691 
entry of potentially harmful antigens that could enter through the oral route. Wang et al. 692 
(2000) showed that the administration of LF and its pepsin hydrolysate increased the mucosal 693 
immune response in mice, and this increase was higher in tumor bearing mice, suggesting an 694 
anti-metastasis and anti-carcinogenesis activity mediated by IL-18 production. In piglets, the 695 
ingestion of a LFcin-lactoferrampin mixture increased serum IgA, IgG and IgM levels, thus 696 
improving the immune function and gut health (Tang et al., 2009). 697 
Several studies have shown that peptides released from milk fermented with 698 
Lactobacillus helveticus R389 are able to improve the mucosal immune system in non-699 
infected (LeBlanc, Matar, Valdéz, LeBlanc, & Perdigón, 2002; Vinderola, Matar, Palacios, & 700 
Perdigón, 2007a; Vinderola, Matar, & Perdigón, 2007b) or Escherichia coli O157:H7 infected 701 
mice (LeBlanc, Fliss, & Matar, 2004), as well as to decrease the development of induced 702 
fibrosarcoma in mice (LeBlanc et al., 2002). On the other hand, a tryptic CN hydrolysate has 703 
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also shown an immunostimulatory activity in newborn calf partly due to the capacity of this 704 
hydrolysate to stimulate the autolytic microbial system (Biziulevičius et al., 2003). Likewise, 705 
an immunomodulatory activity of CPPs was shown in mice fed ovoalbumin-based diet 706 
supplemented with these peptides that was mediated by an increase of IgA levels in serum, 707 
intestine, and faeces towards β-Lg injected peritoneally or bacterial LPS of Salmonella 708 
typhimurium orally administered (Otani, Kihara, & Park, 2000; Otani, Nakano, & Kawahara, 709 
2003). These authors attributed these effects to an increase in IL-5 and IL-6 levels (Otani et 710 
al., 2003). A previous study reported increased IgA level in human faeces after the ingestion 711 
of cake supplemented with CPPs (Kitamura & Otani, 2002), with this effect being higher in 712 
people that ingested dairy products with low frequency. 713 
Despite all these studies where an immunomodulant activity of different hydrolysates 714 
obtained from milk proteins was observed, the peptides responsible for this activity remain 715 
unidentified. Thus, further studies intended to identify these sequences, elucidate their 716 
mechanism of action, and discover new bioactive sequences are needed.  717 
  718 
3.3.3. Antiproliferative peptides 719 
Currently, cancer is the second leading cause of mortality worldwide. It is well known 720 
that 90-95% of cancer cases are attributed to environment and lifestyle factors, including 721 
tobacco and alcohol consumption, diet, sun exposure, pollutants, infections, stress, obesity, 722 
and physical inactivity (Anand et al., 2008). Among these factors, dietary patterns and food 723 
components are closely associated with several types of cancer, being responsible for the 35% 724 
of cancer deaths (Manson, 2003). However, in vitro and in vivo studies have revealed that a 725 
large number of food compounds could lower cancer risk and even sensitize tumor cells to 726 
anti-cancer therapies (de Kok, van Breda, & Manson, 2008).  727 
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In the last few years, food protein-derived peptides have become a group of 728 
nutraceuticals with demonstrated activity preventing the different stages of cancer, including 729 
initiation, promotion, and progression (de Mejia & Dia, 2010). Among the milk derived 730 
peptides, LFcin B is the most extensively studied. As shown in Table 4, LFcin has 731 
demonstrated, by cell culture experiments, a potent activity against different types of cancer 732 
cell lines, including breast, colon, fibrosarcoma, leukemia, oral, and ovarian cancer cells, 733 
without harming normal lymphocytes, fibroblasts, endothelial, or epithelial cells (Furlong, 734 
Mader, & Hoskin, 2010). The selectivity of action of this peptide seems to be due to its 735 
strongly cationic character that allows it to interact with negatively charged structures on 736 
cancer cells, resulting in the destabilization of cancer cell membranes (Hoskin & 737 
Ramamoorthy, 2008). However, the net neutral charge of healthy non-transformed cells keeps 738 
them spared. In addition to this mechanism of action related to its cationic nature, LFcin has 739 
been shown in vitro to act inducing apoptosis, arresting cell cycle, modulating gene 740 
expression, and preventing the angiogenesis (de Mejia & Dia, 2010).  741 
In vivo evidence has revealed that subcutaneous administration of LFcin B resulted in 742 
a significant inhibition of tumor growth and liver and lung metastases of lymphoma and 743 
melanoma cells in spontaneous and experimental metastasis mice models (Yoo et al., 1997a). 744 
Moreover, these authors demonstrated the capacity of this peptide to reduce the number of 745 
tumor-induced blood vessels inhibiting tumor angiogenesis. Subcutaneous treatment of Meth 746 
A fibrosarcoma mice xenografts with LFcin B significantly inhibited tumor growth (Eliassen 747 
et al., 2002). Same effect was observed after treating established neuroblastoma xenografts 748 
with repeated injections of this peptide (Eliassen et al., 2006).  749 
The ability of CPPs to bind calcium has been demonstrated to be responsible for the 750 
protective effect of these peptides from toxicity caused by calcium overload in differentiated 751 
intestinal cells, preventing their apoptosis (Perego et al., 2013). In addition, CPPs act against 752 
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intestinal tumor HT-29 and AZ-97 cells inhibiting their proliferation and inducing 753 
programmed cell death through activation of voltage-activated calcium channels, which 754 
mediate the calcium flood according to the depolarization state of the cell (Perego, Cosentino, 755 
Fiorilli, Tettamanti, & Ferraretto, 2012).  756 
Opioid CN-derived peptides, β-Casomorphin 7 and β-Casomorphin 5, have also shown 757 
antiproliferative and cell cycle arresting activity on breast cancer cells (Hatzglou, 758 
Bakogeorgou, Hatzoglou, Martin, & Castanas, 1996; Maneckjee, Biswas, & Vonderhaar, 759 
1990). It has been suggested that these effects are mediated by interaction with opioid 760 
receptors. Similarly, the interaction with specific opioid and somatostatin receptors present in 761 
the intestinal tract of mammals might be responsible for the antiproliferative effects on colon 762 
cancer cells demonstrated for these β-casomorphins and other milk-derived opioid peptides 763 
(Pepe, Tenore, Mastrocinque, Stusio, & Campiglia, 2013). 764 
 765 
3.4. Effects on the nervous system 766 
 3.4.1. Relaxing peptides 767 
The popular sedative and calming properties of milk can be attributed to various 768 
compounds including proteins and peptides released during digestion. In fact, α-casozepine 769 
(YLGYLEQLLR), a peptide derived from tryptic hydrolysis of αs1-CN, with benzodiazepine-770 
like activity has shown anticonvulsant and anxiolytic activities in rats (Miclo et al., 2001). 771 
However, the mechanism of action of the tryptic hydrolysate differs from that of diazepam. 772 
While diazepam induced a disinhibition state in rats, the tryptic hydrolysate did not display 773 
such a side effect (Violle et al., 2006) despite its affinity for gamma-aminobutyric acid 774 
(GABA) type A receptors. Specific linking of bovine αs1-CN tryptic hydrolysate-derived 775 
peptides on GABA receptor is involved in anxiolysis, but not on that implied in memory-776 
imparing effects (Messaoudi, Lalonde, Schroeder, & Desor, 2009). A fragment, 777 
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corresponding to sequence αs1-CN f(91-97) could be the responsible for the in vivo activity of 778 
α-casozepine (Cakir-Kiefer et al., 2011). Oral intake of an encapsulated αs1-CN tryptic 779 
hydrolysate, containing this peptide, before a stressing situation, decreases the blood pressure 780 
increase induced by the stress. Moreover, the plasma cortisol concentration decreased in the 781 
treated subjects compared to those who have taken a placebo (Messaoudi, Lefranc-Millot, 782 
Desor, Demagny, & Bourdon, 2005). In another study, the oral intake of the encapsulated 783 
hydrolysate by female volunteers significantly reduced their digestive, cardiovascular, 784 
intellectual, emotional and social stress-related symptoms (Kim et al, 2007). 785 
Moreover, it has been reported an anti-stress effect of LF in the neonatal maternal 786 
separation model (Takeuchi et al., 2003), and in an elevated plus-maze test combined with an 787 
electric foot-shock in adult rats (Kamemori, Takeuchi, Hayashida, & Harada, 2004).  788 
  789 
3.4.2. Antinociceptive peptides 790 
Pain receptors or nociceptors are nerve endings found in the tissues of various organs 791 
and systems, characterised by distinguishing securely and efficiently a harmless event from 792 
another. It has been reported that milk proteins such as LF reduces nociceptive activity 793 
mediated by μ-opioid receptor in several models of pain in rats (Hayashida, Takeuchi, 794 
Shimizu, Ando, & Harada, 2003a). Moreover, these authors have demonstrated that the 795 
analgesia induced by spinal administration of morphine was greatly potentiated by 796 
coadministration of LF (Hayashida, Takeuchi, Shimizu, Ando, & Harada, 2003b), and that LF 797 
may block the development of tolerance to morphine in mice, possibly via the selective 798 
activation of NO synthase (Tsuchiya et al., 2006). Raju, Kumar, Arutselvan, Thejomoorthy, 799 
and Puvanakrishan (2005) have found that PEEP1261, a tetrapeptide corresponding to f(39-800 
42) of human LF possesses antinoceptive activity with optimal effect at 40 mg kg-1 body 801 
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weight in both tail-flick model and acetic acid induced writhing in rats. Furthermore, it was 802 
observed that this peptide exhibited also antipyretic activity. 803 
 804 
4. Future prospects 805 
Beyond their well-known nutritional value, milk proteins may exhibit a plethora of 806 
biological activities that influence the growth, development and function of specific organs, 807 
metabolic responses to absorbed nutrients, and defence systems, among others. Many of these 808 
activities could be exerted by peptides released from parent protein during gastrointestinal 809 
digestion or food processing. The research area of bioactive peptides is only at its beginning 810 
and more sequences along with additional physiological effects will be discovered in the 811 
future. Most of the properties of milk bioactive peptides have been demonstrated by in vitro 812 
assays and/or animal model systems. However, data obtained from these studies are 813 
insufficient to demonstrate efficacy of those peptides in humans. Evaluation of the peptide 814 
doses and treatment durations, and elucidation of the molecular mechanisms of actions are 815 
still required for many bioactive peptides. So far, evidence for such effect exists only for a 816 
few proteins and peptides, and once the beneficial effect has been demonstrated in acute 817 
human intervention studies cannot be always translated to longitudinal effects. In order to 818 
generate evidence of these beneficial effects, further long-term human trials using sufficient 819 
number of subjects, controlled doses and formulations are needed. It has been proposed that 820 
discrepancies found in some clinical trials could be due to human diversity and phenotypic 821 
differences between individuals. In this context, future clinical trials of food bioactives could 822 
benefit from data on genotype, metabolomic profiles and proteomics or transcriptomics data 823 
of the volunteers. In these studies, there is also a need to identify and validate biomarkers that 824 
conclusively be related to a certain health benefit. It is expected that new biomarkers will be 825 
developed using novel approaches including functional genomics, food metabolomics, 826 
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microbiomics and epigenetics, and by exploring markers in human studies based on foods and 827 
diets, and not just their individual ingredients. Bioavailability of food peptides is also crucial 828 
in these studies, since it is dependent of numerous factors such as the food matrix, food 829 
composition but also it may vary between individuals. Finally, it has to be taken into account 830 
that the pharmacological approach is not always applicable to food bioactives where the 831 
physiological effects are smaller. Scientific progress in the field must be targeted at a better 832 
understanding of how these food-derived peptides interact with the human body and can 833 
prevent the initiation, development or progression of risk factors for diet-related chronic 834 
diseases. 835 
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